Medtronic Receives FDA Clearance for MiniMed Go Smart MDI System with Abbott's Instinct Sensor
核心洞察
Medtronic announced FDA 510(k) clearance for its MiniMed Go (搜索) Smart Multiple Daily Injection system, integrating the InPen (搜索) smart insulin pen with Abbott's Instinct sensor (搜索) through a unified app.
The system addresses the needs of over 15 million people worldwide who rely on multiple daily injections, providing missed dose alerts, dose calculations, and actionable guidance to reduce diabetes management burden.
Real-world data from the previous generation system showed Time in Range increased from 55.7% to 67.2% when users addressed more than 75% of missed dose alerts within an hour.
Medtronic announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its MiniMed Go (搜索) app, marking the launch of what the company describes as the first and only smart Multiple Daily Injection (MDI) system that automatically integrates insulin dosing and glucose data in a single application. The MiniMed Go Smart MDI system seamlessly connects the InPen (搜索) smart insulin pen with Abbott's Instinct sensor (搜索) through the MiniMed Go app.
The integrated system delivers real-time, personalized insights and actionable guidance, including missed dose alerts to help minimize glucose highs, a dose calculator that simplifies dose decision-making, action-oriented guidance for missed or miscalculated doses, and CareLink software reporting for enhanced provider collaboration.
Regulatory Approval and Patient Population
The MiniMed Go (搜索) system received clearance for individuals with insulin-requiring type 1 and type 2 diabetes aged 7 years and older, as well as for children ages 2 to 6 years under adult caregiver supervision. Compatibility of the Simplera (搜索) sensor with MiniMed Go is currently under FDA review.
Addressing Critical Unmet Medical Need
The system targets a significant patient population, with more than 15 million people worldwide with diabetes relying on multiple daily injections. For these individuals, mealtimes present ongoing challenges involving carbohydrate calculation and insulin dose determination to maintain blood sugar levels and avoid dangerous glucose fluctuations.
The clinical impact of missed insulin doses is substantial. According to research cited by Medtronic, skipping just two doses per week can raise HbA1C by as much as 0.4%, increasing the risk of both short- and long-term complications. The company emphasizes that insulin dosing represents more than a mathematical challenge—it constitutes a daily burden that adds stress and fatigue to diabetes management.
Clinical Evidence and Performance Data
Real-world data from the previous generation Medtronic Smart MDI system demonstrated meaningful improvements in glycemic control when users consistently responded to actionable alerts. The data showed Time in Range (TIR) increased from 55.7% to 67.2% when users addressed more than 75% of Missed Dose alerts within an hour, and further improved to 71.5% when users addressed Correct High Glucose alerts with a bolus within an hour.
These results, according to Medtronic, underscore the power of timely, actionable insights in helping users achieve better glycemic outcomes. The new MiniMed Go (搜索) Smart MDI System builds on this foundation to deliver real-time, personalized insights and actionable guidance.
Technology Integration and Features
The system combines three key components: the InPen (搜索) smart insulin pen, which uses Bluetooth technology to send dose information to a mobile app and offers dose calculations and tracking; Abbott's Instinct sensor (搜索), which provides up to 15 days of wear in what Abbott describes as the world's smallest and thinnest integrated continuous glucose monitor; and the MiniMed Go (搜索) app that connects these devices.
"For too long, people using injections have carried the weight of diabetes management without access to the algorithms that make automated insulin delivery systems so powerful," said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. "MiniMed Go (搜索) is designed to change that—bringing the smarts of an AID system to individuals who prefer an insulin pen. The system helps take the guesswork out of MDI therapy, delivering simplicity and confidence in every dose."
Commercial Launch Timeline
Medtronic expects the commercial launch of the MiniMed Go (搜索) system to begin in the U.S. this spring. The company positions this launch as part of its strategy to expand full-stack insulin delivery solutions, making it easier for customers to find appropriate therapy regardless of their position in the diabetes management journey.